Page 96 - Demo

Chapter 594Table 3. Association of miRNA expression with OS and PFS. Abbreviations: n, number of patients; H - L, high vs low miRNA expression; HR, hazard ratio; OS, overall survival (months); PFS, progression-free survival (months); P, p-value; vs., versus; GC, gastric cancer; EAC, oesophageal adenocarcinoma; ESCC, oesophageal squamous cell carcinomaOrigin miRNA n; H-L HR (95% CI) P Median OS (CI) HR (95% CI) P Median PFS (CI)GC 141-3p 4-3 1.6(0.4-7.3)0.5 5.1 (0.3-8.7)vs.4.6 (2.7-43.3)1.4(0.3-6.0)0.7 6.8 (0.3-8.7)vs.4.5 (1.8-33.5)GC 200c-3p 5-5 2.9(0.7-11.8)0.06 2.8 (0.3-8.7)vs.11.1 (4.3-43.3)2.4(0.6-9.5)0.1 1.6(0.3-8.7)vs.8.1(1.8-33.5)GC 146a-5p 5-5 1.4(0.4-4.9)0.6 7.7 (2.8-11.1)vs.4.6 (0.3-43.3)1.5(0.4-5.2)0.5 6.8 (1.6-8.7)vs.4.6 (0.3-33.5)GC 218-5p 3-3 1.7(0.3-8.8)0.5 2.8 (0.11-8.7)vs.4.6 (0.3-43.3)1.7(0.3-8.8)0.5 1.6 (0.11-8.7)vs.4.5 (0.3-23.3)EAC 375 9-9 0.4(0.1-1.1)0.02 14.9 (5.4-20.4)vs.10.1 (3.1-17.2)0.5(0.2-1.3)0.1 6.1 (3.0-17.5)vs.5.4 (1.5-7.7)EAC 200c-3p 9-9 0.7(0.3-1.8)0.4 10.3 (3.1-0.4)vs.11.8 (4.0-18.1)1.2(0.5-3.0)0.7 5.4(1.5-17.5)vs.6.0 (1.5-11.3)EAC 21-5p 9-9 0.7(0.3-1.9)0.5 10.3 (3.1-20.4)vs.11.8 (4.0-18.1)1.0(0.4-2.6)1.0 5.5 (1.5-17.5)vs.5.9 (1.5-11.3)EAC 148a-3p 8-9 0.5(0.2-1.4)0.2 14.2 (5.4-20.4)vs.10.3 (3.1-18.1)0.9(0.3-2.2)0.7 5.8 (3.0-17.5)vs.5.4 (1.5-11.3)GC+ AEC200c-3p 14-14 1.5(0.7-3.1)0.3 8.2 (0.26-20.4)vs.11.5 (4.0-43.3)1.7(0.8-3.8)0.1 5.0 (0.26-17.5)vs.6.4 (1.5-33.5)ESCC 200c-3p 4-4 1.52(0.4-6.3)0.5 7.4 (3.7-9.7)vs.5.8 (0.03-9.9)1.0(0.3-4.0)1.0 6.0 (3.7-7.9)vs.3.4 (0.03-8.7)ESCC 375 4-4 1.5(0.4-6.3)0.5 6.6 (0.03-9.7)vs.7.5 (1.9-9.9)1.5(0.4-6.3)0.5 4.2 (0.03-7.9)vs.6.0 (1.9-8.7)ESCC 21-5p 4-4 0.4(0.1-1.8)0.1 9.6 (3.7-9.9)vs.3.6 (0.03-9.7)0.4(0.1-1.8)0.1 6.3 (3.7-8.7)vs.3.3 (0.03-7.3)ESCC 148a-3p 4-4 0.4(0.1-1.8)0.1 9.6 (3.7-9.9)vs.3.6 (0.03-9.7)0.4(0.1-1.8)0.1 6.3 (3.7-8.7)vs.3.3 (0.03-7.3)